Cadrenal Therapeutics, Inc. Common Stock (CVKD) vs Processa Pharmaceuticals, Inc. (PCSA)

A side-by-side comparison of Cadrenal Therapeutics, Inc. Common Stock and Processa Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Cadrenal Therapeutics, Inc. Common Stock logo
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$4M
$1.04HealthcareDelayed quote: Oct 6, 2026, 3:04 PM EDT
Processa Pharmaceuticals, Inc. logo
PCSA
Processa Pharmaceuticals, Inc.
$4M
$1.49HealthcareDelayed quote: Oct 6, 2026, 2:48 PM EDT

Total return — CVKD vs PCSA

growth of $100 · dividends reinvested · last 4y
CVKD -98.5% (-64.8%/yr)PCSA -99.8% (-77.8%/yr)CVKD compounded faster over this window
Log scale — wide-divergence pair
0110100Start $100202420252026$2$0
CVKD PCSA

CVKD vs PCSA: by the numbers

  • •PCSA is the larger company ($4M vs $4M market cap).

Metrics side by side

Valuation

MetricCVKDPCSA
P/B ratio0.91N/A

Profitability

MetricCVKDPCSA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-282.13%N/A
ROIC-284.81%N/A

Growth (annualized)

MetricCVKDPCSA
Total return CAGR (5Y)N/A-79.32%

Go deeper

Full CVKD analysisFull PCSA analysisInteractive comparison tool

Dig into the metrics

Cadrenal Therapeutics, Inc. Common Stock ROEProcessa Pharmaceuticals ROECadrenal Therapeutics, Inc. Common Stock operating marginProcessa Pharmaceuticals operating marginCadrenal Therapeutics, Inc. Common Stock revenue growthProcessa Pharmaceuticals revenue growthCadrenal Therapeutics, Inc. Common Stock free cash flowProcessa Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.